These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32107929)

  • 1. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
    Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
    Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
    Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
    J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
    [No Abstract]   [Full Text] [Related]  

  • 3. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
    Shi Y; Wan X; Tan C; Li J; Peng L
    Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.
    Harty G; Jarrett J; Jofre-Bonet M
    Appl Health Econ Health Policy; 2018 Aug; 16(4):515-525. PubMed ID: 29948926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of selective first-line use of biologics for unresectable
    Wong WWL; Zargar M; Berry SR; Ko YJ; Riesco-Martínez M; Chan KKW
    Curr Oncol; 2019 Oct; 26(5):e597-e609. PubMed ID: 31708653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia.
    Elsamany S; Elsisi GH; Mohamed Hassanin FA; Saleh K; Tashkandi E
    Value Health Reg Issues; 2022 Mar; 28():67-75. PubMed ID: 34801961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S
    Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
    BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
    Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
    Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
    Wu Q; Zhang P; Wang X; Zhang M; Liao W; Li Q
    Clin Ther; 2020 Nov; 42(11):2148-2158.e2. PubMed ID: 32981743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.
    Zhou J; Zhao R; Wen F; Zhang P; Tang R; Chen H; Zhang J; Li Q
    Medicine (Baltimore); 2016 Jul; 95(27):e3762. PubMed ID: 27399059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
    Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
    Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
    J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.